Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Accrued expenses and other long-term liabilities, excluding National, consisted of the following:

	June 30,		December 31,
($ in thousands)	2017		2016
Accrued expenses:
Professional fees	$	1,748	$	1,253
Salaries, bonuses and related benefits		2,295		2,846
Accrued Severance		-		53
Ovamed manufacturing rights - short term component		-		900
Research and development		2,914		394
Dr. Falk Pharma milestone		2,852		2,634
Other		2,564		2,002
Total accrued expenses	$	12,373	$	10,082

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge		5,026		5,014
Total other long-term liabilities	$	5,026	$	5,014

National's accounts payable and other accrued expenses as of March 31, 2017, consisted of the following:

	March 31,
	2017
Legal	$	766
Audit		287
Telecommunications		187
Data Services		348
Regulatory		1,061
Settlements		1,131
Deferred rent		630
Contingent consideration payable		121
Other		2,592
Total	$	7,123